Drawing for PATCHLESS PATCH

USPTO serial 78288099

PATCHLESS PATCH

Reviewed by CopyMark Law Group

Reg. 3062095Status 710
Filing date
Status date
Registration date
Feb 28, 2006
Examiner
CRAWFORD, MARY
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with PATCHLESS PATCH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

STEPHEN A BENT

STEPHEN A BENT LARDNER3000 K ST NW STE 500WASHINGTON, DC 20007UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and veterinary preparations for the treatment of symptoms of menopause, female androgen insufficiency, severe pain, for the treatment of central nervous system disorders including nausea and anxiety-related disorders, male androgen insufficiency, urinary incontinence, for contraception and smoking cessation; pharmaceutical compositions for transdermal delivery for the treatment of symptoms of menopause, female androgen insufficiency, severe pain, for the treatment of central nervous system disorders including nausea and anxiety-related disorders, male androgen insufficiency, urinary incontinence, for contraception and smoking cessation; pharmaceutical compositions for transmucosal delivery for the treatment of symptoms of menopause, female androgen insufficiency, severe pain, for the treatment of central nervous system disorders including nausea and anxiety-related disorders, male androgen insufficiency, urinary incontinence, for contraception and smoking cessation; pharmaceutical compositions for hormone-replacement therapy; pharmaceutical compositions containing active agents for the treatment of diseases and conditions of the central nervous system; pharmaceutical compositions for non-occlusive transdermal and transmucosal delivery which form a reservoir or deposit within the skin or membrane for the treatment of symptoms of menopause, female androgen insufficiency, severe pain, for the treatment of central nervous system disorders including nausea and anxiety-related disorders, male androgen insufficiency, urinary incontinence, for contraception and smoking cessation; pharmaceutical compositions providing transdermal and transmucosal delivery of hormones such as estradiol and other physiologically active agents acting on the central nervous system such as fentanylSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 5, 2012C8..CANCELLED SEC. 8 (6-YR)—
Feb 28, 2006R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 6, 2005PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 16, 2005NPUBNOTICE OF PUBLICATION—
Oct 14, 2005PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Sep 16, 2005ALIEASSIGNED TO LIE—
Sep 10, 2005CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 9, 2005TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 6, 2005CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 6, 2005TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 7, 2005CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 6, 2005CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 19, 2004CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 17, 2004ACECAMENDMENT FROM APPLICANT ENTERED—
Nov 9, 2004MAILPAPER RECEIVED—
Sep 16, 2004ACECAMENDMENT FROM APPLICANT ENTERED—
Sep 16, 2004ALIEASSIGNED TO LIE—
Aug 17, 2004CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 17, 2004MAILPAPER RECEIVED—
Feb 17, 2004CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 30, 2004DOCKASSIGNED TO EXAMINER—
Nov 17, 2003MAILPAPER RECEIVED—

Frequently asked questions

Related guidance